Enhanced CAR T-Cell Therapy Tested for Hard-to-Treat Lymphomas

Elicera Therapeutics announced that the first patient has been enrolled in the company's Phase I/II clinical study, CARMA.

Immunotherapy is increasingly recognized as the fourth pillar of cancer treatment alongside radiation, surgery, and chemotherapy. A new clinical trial at Akademiska Hospital is testing enhanced CAR T-cells, developed at Uppsala University, targeting patients with lymphomas unresponsive to or relapsed after existing CAR T-cell therapies.

This enhanced therapy, CAR20(NAP)-T cells, targets the CD20 protein, often overexpressed in lymphomas and leukemias. It also releases a bacterial protein (NAP) to stimulate a stronger immune response against tumors. The first patient has been treated, and 18 participants will be enrolled, with initial focus on finding the optimal dose.

The therapy, refined by Elicera Therapeutics, may offer curative potential for resistant cancers and is being explored for other diseases, including gliomas.

About CAR T-Cells

• CAR T-cells are modified patient T-cells designed to identify and kill cancer cells.
• Approved for some lymphomas and leukemias, the therapy is now being tested for broader applications, including inflammatory diseases like MS and SLE.

About ATMP Center Uppsala
The ATMP Center, established in 2023, supports the development of advanced therapies like CAR T-cells, driving innovation in cell and gene therapies.

Orginal articles:

https://via.tt.se/pressmeddelande/3688805/ny-studie-forstarkt-car-t-cellsbehandling-provas-vid-svarbehandlade-lymfom?lang=sv

https://www.elicera.com/press-releases/elicera-therapeutics-includes-the-first-patient-in-the-phase-i-ii-clinical-study-carma-targeting-b-cell-lymphoma